Research Paper Volume 15, Issue 10 pp 4363—4373

Figure 2. Role of suppressing STAT1 in mouse colitis. (A) Dynamic measurement of mouse body weight (n=10). Weight loss in mice of Cirsilineol group was mitigated relative to DSS group. ^*P<0.05 vs. Control group, ^#P<0.05 vs. DSS group. (B) DAI dynamic score (n=10). The DAI score of Cirsilineol group was lower than that of DSS group. ^*P<0.05 in relative to Control group, ^#P<0.05 in relative to DSS group. (C) Mouse intestinal length (n=10). Cirsilineol group had increased intestinal length compared with DSS group. ^*P<0.05 vs. Control group, ^#P<0.05 vs. DSS group. (D) FITC-D (n=10). Cirsilineol reduced serum FITC-D content, with significant difference relative to DSS group. ^*P<0.05 in relative to Control group, ^#P<0.05 in relative to DSS group. (E–G) ELISA (n=10). Cirsilineol decreased IL-2, IFN-γ, TNF-α, IL-6 and IL-1β contents in tissues, while IL-4, IL-10 and IL-13 (markers of Th2 cells) expression remained largely unchanged. ^*P<0.05 vs. Control group, ^#P<0.05 vs. DSS group. (H, I) Relative protein expression levels (n=5). Cirsilineol increased tissue TJ protein levels, but decreased the PCSK6 as well as p-STAT1 levels. ^*P<0.05 vs. Control group, ^#P<0.05 vs. DSS group. (J–M) Relative to DSS group, Th1 cells and M1 macrophages proportions of Cirsilineol group remarkably declined, with significant differences. ^*P<0.05 vs. Control group, ^#P<0.05 vs. DSS group.